February 21, 2019



  • Liu, M., Wang, S.J. and Ji, Y., (2019). The i3+ 3 Design for Phase I Clinical Trials. arXiv preprint arXiv:1901.01303.
  • Guo, W., Ji, Y., & Li, D. (2019). R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials. Journal of biopharmaceutical statistics, 1-14.


  • Lyu, J., Curran, E., Ji, Y. (2018). BaSyc: A Bayesian Adaptive Dose-Cycle Finding Design. (Accepted) JCO Precision Oncology.


  • Guo, W., Ji, Y., & Catenacci, D. V. (2017). A subgroup cluster‐based Bayesian adaptive design for precision medicine. Biometrics, 73(2), 367-377.
  • Guo, W., Wang, S. J., Yang, S., Lynn, H., & Ji, Y. (2017). A Bayesian interval dose-finding design addressingOckham’s razor: mTPI-2. Contemporary clinical trials, 58, 23-33.


  • Li, D. H., Whitmore, J. B., Guo, W., & Ji, Y . Toxicity and Efficacy Probability Interval Design for Phase 1 Adoptive Cell Therapy Dose-Finding Clinical Trials. Clinical Cancer Research, clincanres-1125.
  • Guo, W, Ji, Y* and Catenacci, D. A Subgroup Cluster Based Bayesian Adaptive Design for Precision Medicine. Biometrics, 73(2), 367-377.


  • Yang, S, Wang, SJ, Ji, Y* Integrated Dose-Finding Tool for Phase I Trials in Oncology. Contemporary Clinical Trials. 2015. 45:426-434.
  • Guo W, Ni Y, Ji Y* TEAMS: Toxicity- and Efficacy-based Dose Insertion Design with Adaptive Model Selection for Phase I/II Dose-Escalation Trials in Oncology. Statistics in Biosciences. 2015. 7(2):432-459.
  • Lee, JH, Thall, PF, Ji Y, Mueller, P. Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity. Journal of American Statistical Association. 2015. 110(510):711-722


  • Xu Y, Trippa L, Mueller P, Ji Y*. Subgroup-Based Adaptive (SUBA) Designs for Multi-Arm Biomarker Trials. Statistics in Biosciences In press.
  • Pan H, Xie F, Liu P, Xia J*, Ji Y*. A Phase I/II Seamless Dose Escalation/Expansion with Adaptive Randomization Scheme (SEARS). Clinical Trials. 2014; 11(1):49-59.
  • Cai C, Ji Y, Ying Y. A Bayesian Dose-finding Design for Oncology Clinical Trials of Combinational Biological Agents. Journal of Royal Statistical Society, Series C (Applied Statistics). 2014;63(1):159-173.


  • Ji Y*, Wang S-J. The mTPI Design: A Safer and More Reliable Method than the 3+3 Design for Practical Phase I Trials. Journal of Clinical Oncology. 31(14):1785-91, 2013.


  • Xie F, Ji Y, Tremmel LT. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials. Contemporary Clinical Trials. 33(4):739-48, 07/2012.


  • Hu B, Bekele BN, Ji Y*. Adaptive Dose Insertion in Early Phase Clinical Trials. Clinical Trials. e-Pub 9/2010.
  • Bekele BN, Li Y, Ji Y. Risk-group-specific dose finding based on an average toxicity score. Biometrics 66:541-8, 6/2010.


  • Ji Y, Bekele BN. Adaptive randomization for multi-arm comparative clinical trials based on joint efficacy/toxicity outcomes. Biometrics 65:876-84, 9/2009.


  • Bekele BN, Ji Y, Shen Y, Thall PF. Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics 9:442-57, 7/2008.
  • Li Y, Bekele BN, Ji Y, Cook JD. Dose-schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation. Stat in Med 27:4895-4913, 10/2008.


  • Ji Y, Li Y, Yin G. Bayesian dose-finding designs for phase I clinical trials. Statistica Sinica 17:531-47, 2007.
  • Ji Y, Li Y, Nebiyou Bekele B. Dose-finding in phase I clinical trials based on toxicity probability intervals. Clinical Trials 4:235-44, 2007.